Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ReShape Lifesciences, Inc. - Common Stock (NQ:RSLS)

4.180 -0.070 (-1.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ReShape Lifesciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
ReShape Lifesciences® to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
Conference Call to be Held at 8:00 am ET on Wednesday, March 29, 2023 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Present at the Q2 Virtual Investor Summit
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences(TM) (NASDAQ: RSLS) Featured in Coverage of Investor Summit Group’s Q4 Event
Via Investor Brand Network
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Conference Call to be Held at 8:00 am ET Today 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences Announces $750,000 Registered Direct Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences™ to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
Conference Call to be Held at 8:00 am ET on Monday, November 14, 2022 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®
Stimulation of Vagus Celiac Fibers with Concurrent High Frequency Alternating Current Block of Hepatic Fibers Decreases Glucose Variability in a Swine Model of Type 2 Diabetes 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences to Present at the Q4 Investor Summit
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences™ Announces Publication of Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) System in Peer Reviewed, Frontiers in NeuroScience
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences™ Announces Release of a Positive Consensus Statement on Lap-Band® Use and Lap-Band® Aftercare Management by the American Society of Metabolic and Bariatric Surgery (ASMBS)
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences(TM) (NASDAQ: RSLS) Featured in Coverage of Investor Summit Group’s Q2 Virtual Event
Via Investor Brand Network
ReShape Reports Second Quarter 2021 Financial Results and Provides Business Update
Webinar to follow at 8:30 a.m. today SAN CLEMENTE, CA / ACCESSWIRE / August 16, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a leading developer and distributor of minimally invasive medical devices... 
From ReShape Lifesciences Inc.
Via AccessWire
ReShape Lifesciences Reports Preliminary Unaudited Second Quarter 2021 Financial Results and Provides Business Update
SAN CLEMENTE, CA / ACCESSWIRE / August 5, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic... 
From ReShape Lifesciences Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
ReShape Lifesciences(TM) CEO Bart Bandy Featured on the Big Biz Show
SAN CLEMENTE, CA / ACCESSWIRE / August 3, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss solutions company, today announced CEO Bart Bandy's featured interview on... 
From ReShape Lifesciences Inc.
Via AccessWire
ReShape Lifesciences to Report Second Quarter 2021 Financial and Operational Results on Thursday, August 5, 2021
Webinar will be available discussing recent major milestones that same day SAN CLEMENTE, CA / ACCESSWIRE / July 29, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss... 
From ReShape Lifesciences Inc.
Via AccessWire
ReShape Lifesciences(TM) Launches Online Consumer Marketplace Offering Products Supporting Four Key Dimensions of Wellness: Nutrition, Exercise, Sleep and Stress
SAN CLEMENTE, CA / ACCESSWIRE / July 13, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the launch of... 
From ReShape Lifesciences Inc.
Via AccessWire
ReShape Lifesciences Moves Lap-Band Manufacturing to United States
SAN CLEMENTE, CA / ACCESSWIRE / July 7, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced it has completed... 
From ReShape Lifesciences Inc.
Via AccessWire
ReShape Lifesciences Sees Lap-Band Growth as COVID-19 Pandemic Heightens Obesity Crisis
SAN CLEMENTE, CA / ACCESSWIRE / July 1, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight-loss solutions company, today announced that Lap-Band® utilization has increased... 
From ReShape Lifesciences Inc.
Via AccessWire
Exposures COVID-19
ReShape Lifesciences Completes $46 Million Capital Raise With Key Institutional Shareholders
Funding provides for the acceleration of its internal growth strategy and the continued development of Reshape's weight-loss portfolio SAN CLEMENTE, CA / ACCESSWIRE / June 30, 2021 / ReShape... 
From ReShape Lifesciences Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
ReShape Lifesciences Enters into Warrant Exercise Transaction for $46.2 Million in Gross Proceeds
SAN CLEMENTE, CA / ACCESSWIRE / June 29, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a global weight-loss solutions leader, announced today that it has entered into a warrant exercise agreement... 
From ReShape Lifesciences Inc.
Via AccessWire
ReShape Lifesciences Closes First Day of Trading on the NASDAQ Capital Market
Shares of ReShape Lifesciences commenced trading on The Nasdaq Capital Market at market open on June 16, 2021 under the ticker symbol "RSLS" SAN CLEMENTE, CA / ACCESSWIRE / June 17, 2021 / ReShape... 
From ReShape Lifesciences Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
ReShape Lifesciences Completes Merger with Obalon Therapeutics
Shares of ReShape Lifesciences to commence trading on The Nasdaq Capital Market on June 16, 2021 under ticker symbol "RSLS" Combination creates opportunity for ReShape to expand portfolio of FDA... 
From ReShape Lifesciences Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Announce Anticipated Closing of Merger
SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 15, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today the anticipated closing of their... 
From ReShape Lifesciences Inc.
Via AccessWire
ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending Merger
SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today that the parties anticipate the... 
From ReShape Lifesciences Inc.
Via AccessWire
Reminder: Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences
SAN DIEGO, CA / ACCESSWIRE / May 24, 2021 / Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled... 
From ReShape Lifesciences Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.